Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome
β Scribed by Masaki Yasukawa; Hiroshi Fujiwara; Toshiki Ochi; Koichiro Suemori; Hiroshi Narumi; Taichi Azuma; Kiyotaka Kuzushima
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 289 KB
- Volume
- 84
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We identified a novel human long fatty acyl CoA synthetase 2 gene, ACS2, as a new ETV6 fusion partner gene in a recurrent t(5;12)(q31;p13) translocation in a patient with refractory anemia with excess blasts (RAEB) with basophilia, a patient with acute myelogenous leukemia (AML) with eosinophilia, a
Gene amplification is one of the mechanisms for activating proto-oncogenes resulting in an enhanced expression of the corresponding gene product. By fluorescence in situ hybridization (FISH), amplification of the proto-oncogene MLL has been described only in seven patients with acute myeloid leukemi
The MLL gene at 11q23 is frequently disrupted by chromosomal translocations in de novo acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), and in secondary leukemia induced by treatment with inhibitors of topoisomerase II, including the epipodophylotoxins. The CBFA2 gene at 21q22 is also